Conversely, the combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib showed promising results and tolerability in BRAF exon 15 p.V600E-mutated unresectable or metastatic anaplastic thyroid carcinoma patients and obtained FDA approval [161]. Here, BRAF is linked to thyroid gland undifferentiated (anaplastic) carcinoma.